Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model
AC102 regenerates connections between the inner ear and auditory nerve in a preclinical model and eliminates tinnitus. Efficacy of AC102 on sudden hearing loss and tinnitus currently investigated in clinical trial.
Share
In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, they nearly disappeared in the AC102 group after five weeks – in clear contrast to the placebo group. Additionally, the AC102 group showed significantly less loss of synaptic connections between the inner ear and the auditory nerve than the placebo group. This damage is considered to be a potential cause of tinnitus: 'Our results suggest regeneration of inner ear structures that are critical for tinnitus and could be an important milestone and a glimmer of hope for a causal treatment of tinnitus,' says the study's first author, Dr. Konstantin Tziridis from Erlangen University Hospital.
About two-thirds of sudden hearing loss patients also suffer from tinnitus, which persists in around 30% of cases. Although 10-15% of adults experience tinnitus, no effective causal treatment exists. AC102 has the potential to become a new treatment option. In a preclinical acoustic trauma model, it almost completely reversed sudden hearing loss. Since tinnitus often accompanies sudden hearing loss, AudioCure is investigating AC102's potential efficacy also against tinnitus in its ongoing study. AudioCure's CEO, Dr. Reimar Schlingensiepen, emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients and doctors who have no approved drug treatment available at present." AC102 has already been tested for safety and tolerability in a clinical study and is currently being examined in a Europe-wide Phase-2-study in patients for its effectiveness in sudden hearing loss and tinnitus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
an hour ago
- Gizmodo
New Research Debunks Myth That Brain Cells Stop Growing After Childhood
You've probably heard the old canard that new brain cells simply stop forming as we become adults. But research out today is the latest to show that this isn't really true. Scientists in Sweden led the study, published Thursday in Science. They found abundant signs of neural stem cells growing in the hippocampus of adult brains. The findings reveal more about the human brain as we get older, the researchers say, and also hint at potential new ways to treat neurological disorders. 'We've found clear evidence that the human brain keeps making new nerve cells well into adulthood,' study co-author Marta Paterlini, a neuroscientist at the Karolinska Institute in Stockholm, told Gizmodo. This Is What Your Brain Looks Like When You Solve a Problem This isn't the first paper to chip away at the idea of new neurons ceasing to form in adulthood (a concept not to be confused with general brain development, which does seem to reach maturity around age 30). In 2013, study researcher Jonas Frisén and his team at the Karolinska Institute concluded that substantial neuron growth—also known as neurogenesis—occurs throughout our lives, albeit with a slight decline as we become elderly. But there's still some debate ongoing among scientists. In spring 2018, for instance, two different studies of neurogenesis published a month apart came to the exact opposite conclusion. The researchers were hoping to settle one particular aspect of human neurogenesis in adults. If we do keep growing new neurons as we age, then we should be able to spot the cells that eventually mature into neurons, neural progenitor cells, growing and dividing inside the adult brain. To look for these cells, the team analyzed brain tissue samples from people between the ages of 0 and 78 using relatively new advanced methods. These methods allowed them to figure out the characteristics of brain cells on an individual level and to track the genes being expressed by a single cell's nucleus. All told, the researchers examined more than 400,000 individual cell nuclei from these samples. And as hoped, they found these progenitor cells along various stages of development in adult brains, including cells just about to divide. They also pinpointed the location within the hippocampus where the new cells appeared to originate: the dentate gyrus, a brain region critical to helping us form certain types of memory. 'We saw groups of dividing precursors sitting right next to the fully formed nerve cells, in the same spots where animal studies have shown adult stem cells live,' said Paterlini, a senior scientist at the Frisén lab. 'In short, our work puts to rest the long-standing debate about whether adult human brains can grow new neurons.' Something Strange Happens to Brains During a Marathon The findings, as is often true in science, foster more questions in need of an answer. Our adult precursor cells seem to have different patterns of gene activity compared to the cells found in pigs, mice, and other mammals with clear evidence of adult neurogenesis, for instance. The researchers also found that some adults' brains were filled with these growing precursors, while others had relatively few. These differences—combined with the team's earlier research showing that adult neurogenesis slows down over time—may help explain people's varying risk of neurological or psychological conditions, the authors say. And likewise, finding a safe way to improve the adult brain's existing ability to grow new cells could help treat these conditions or improve people's recovery from serious head injuries. 'Although precise therapeutic strategies for humans are still being researched, the simple fact that our adult brains can generate new neurons radically changes the way we view lifelong learning, recovery from injury, and the untapped potential of neuronal plasticity,' said Paterlini. There's plenty more to be learned about how our brains change over time. The team is planning to investigate other likely hotspots of neurogenesis in the adult brain, such as the wall of the lateral ventricles (c-shaped cavities found in each of the brain's cerebral hemispheres) and nearby regions. But we can be fairly certain that our neurons keep on growing and replacing themselves into adulthood—at least for some of us.
Boston Globe
an hour ago
- Boston Globe
‘They're playing politics with people's lives': Trump's big bill would slash Planned Parenthood's Mass. budget in half
'They're playing politics with people's lives,' said Ireland. 'It saddens me that the legislature does not see the real humans that are being affected by this decision-making.' Advertisement Ireland, a practicing OB/GYN and assistant professor of obstetrics and gynecology at UMass Memorial Medical Center and UMass Chan Medical School in Worcester, said that in just the past several days, she treated three women with widely different medical needs at the league's clinics. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up One had pre-cancer of the cervix. Another had a sexually transmitted disease that she caught from an unfaithful partner. And a third was about to start a pre-med program at an Ivy League school, got pregnant, and wanted an abortion. 'We provide excellent care based on quality and patient satisfaction and I hate to see that threatened,' Ireland said. The league has four clinics in Boston, Marlborough, Springfield, and Worcester, although abortions are not performed at the one in Marlborough. The clinics provide services such as birth control, Pap smears, breast exams and abortions. Advertisement The league provided 9,462 abortions last year, and more than half of them were achieved using a combination of two medications, mifepristone and misoprostol. Federal law, specifically the 1977 Hyde Amendment, already bans states from using federal Medicaid dollars to pay for abortions. Massachusetts, like more than a dozen mostly blue states, uses its own funds to cover abortions for Medicaid recipients. The legislation that President Trump and Republicans in Congress are pushing would affect federal money that covers other medical services and helps keep clinics running. Michael King, president of the Massachusetts Family Institute, an anti-abortion rights group, said there are 'plenty of other clinics that can address those needs' in Massachusetts if Congress approves the Medicaid cuts. He noted that Planned Parenthood said it performed 402,000 abortions nationwide in its 2023-24 annual report, which King called a record number. He also cited a recent study by the Washington-based Ethics and Public Policy Center, a think tank that says it applies 'the riches of the Jewish and Christian traditions' to law, culture, and politics. The study found that 11 percent of women who had medication abortions experienced serious adverse complications. This rate, which has been cited by Republican members of Congress, was significantly higher than the less than 0.5 percent rate found in clinical trials by the US Food and Drug Administration. 'If Planned Parenthood clinics closing means that the number of abortions declined, then we are very pleased that the lives of more babies will be saved in Massachusetts,' King said. Critics of the Medicaid cuts, however, said congressional Republicans are using the so-called 'Big Beautiful Bill' to knee-cap an organization that they have long opposed. Advertisement Although Planned Parenthood isn't mentioned in the bill, 'all they needed to add was it rhymes with wood or Hollywood,' said Fabiola De Liban, director of sexual and reproductive health at the National Health Law Program, in Los Angeles. Ireland said that if the House approves the bill containing the Medicaid cuts, the Planned Parenthood League of Massachusetts is committed to keeping the doors of all four clinics open and maintaining services. She said the league might seek to provide other services to bolster income, including vasectomies and treatment for perimenopause, the physical and emotional symptoms that often appear as a woman approaches menopause. Perimenopausal care includes hormone therapy, vaginal creams, and certain medications that can help manage symptoms like hot flashes and mood changes. Jonathan Saltzman can be reached at
Associated Press
2 hours ago
- Associated Press
Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook to 2031: United States and China Lead Global Gamma Delta T Cell Therapy Clinical Trials
DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031" report has been added to offering. Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions: Adoptive gamma delta T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aß) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, gamma delta T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. gamma delta T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies. In cancer, gamma delta T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Gamma delta T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor. The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Gamma delta T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability. TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic gamma delta T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global gamma delta T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other gamma delta T cell candidates in development for various cancer indications. One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of gamma delta T cells and substantiates their role as a new therapeutic strategy. Globally, most of the research studies on gamma delta T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply gamma delta T cell treatments to these more difficult contexts. Geographically, US-based players dominate the gamma delta T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside. Moving forward, the prospects for gamma delta T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of gamma delta T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain. Company Coverage: Key Topics Covered: 1. Introduction To Gamma Delta T Cell Therapy 1.1 Emerging Role of T Cell Based Immunotherapies 1.2 Overview of Gamma Delta T Cell Therapy 1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies 2. Role of Gamma Delta T Cells in Cancer 2.1 Gamma Delta T Cells in Cancer Progression 2.2 Anti Tumor Activity of Gamma Delta T Cells 2.3 Adopted Approaches for Gamma Delta T Cell Therapy 3. Advanced Combination Strategies In Gamma Delta T Cell Therapy 4. Gamma Delta T Cell Therapy Market Overview 4.1 Current Market Scenario 4.2 Future R&D & Commercial Opportunities 4.3 Market Potential of Gamma Delta T Cell Therapy Market 4.4 Technology Platforms For Gamma Delta T Cell Therapy 4.5 Favorable Market Growth Parameters 4.6 Key Challenges To Overcome For Future Growth 5. Global Gamma Delta T Cell Therapy Clinical Trials Overview 5.1 By Phase 5.2 By Country 5.3 By Company 5.4 By Indication 5.5 By Priority Status 6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase 6.1 Research 6.2 Preclinical 6.3 Phase I 6.4 Phase I/II 6.5 Phase II 6.6 Phase II/III 7. Gamma Delta T Cell Therapy In Leukemia 7.1 Ongoing Clinical Research & Development Trends 7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia 8. Gamma Delta T Cell Therapy In Lung Cancer 8.1 Ongoing Clinical Research & Development Trends 8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer 9. Gamma Delta T Cells In Breast Cancer 9.1 Ongoing Clinical Research & Development Trends 9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer 10. Gamma Delta T Cells in Colorectal Cancer 10.1 Ongoing Clinical Research & Development Trends 10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer 11. Gamma Delta T Cells In Pancreatic Cancer 11.1 Ongoing Clinical Research & Development Trends 11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer 12. Gamma Delta T Cells In Lymphoma 12.1 Ongoing Clinical Research & Development Trends 12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma 13. Gamma Delta T Cell Therapy In Brain Tumors 13.1 Research & Development In Brain Tumors 13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors 14. Gamma Delta T Cell Therapy In Head & Neck Cancer 14.1 Research & Development In Head & Neck Cancer 14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer 15. Competitive Landscape 15.1 Acepodia 15.2 Adicet 15.3 Appia Bio 15.4 Cytomed Therapeutics 15.5 Century Therapeutics 15.6 Expression Therapeutics 15.7 Immatics 15.8 IN8bio 15.9 JY BioMed 15.10 Legend Biotech 15.11 Luminary Therapeutics 15.12 PhosphoGam 15.13 Takeda 15.14 TC Biopharm 15.15 ViGenCell For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 12:19 PM/DISC: 07/03/2025 12:19 PM
